Setmelanotide

An MC4 receptor agonist approved for rare genetic obesity syndromes.

What research shows

Setmelanotide is a licensed medicine for rare genetic obesity syndromes, with pooled trial evidence and guideline coverage in Bardet-Biedl syndrome. It is prescribed for specific genetic diagnoses. Nothing we verified supports the general weight-loss use it is sometimes marketed for.

Evidence strength

Highest evidence grade among the graded claims: A. Grades reflect study strength, not benefit.

Safety context

See the safety section. Absence of a flag is not evidence of safety.

No endorsement

A grade reflects evidence strength, not a recommendation to use this compound; a strong grade can attach to a harmful effect.